By Dani Kass ( October 5, 2022, 5:17 PM EDT) -- A generic-drug maker told the U.S. Supreme Court on Wednesday not to let Novartis keep its monopoly over the blockbuster multiple sclerosis drug Gilenya while appealing a patent invalidation, saying the pharmaceutical giant will just use that time to overcharge customers before ultimately losing the appeal....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.